Mise rakovina

Příspěvek k řešení významných společenských výzev prostřednictvím tzv. misí je novinkou programu Horizont Evropa pro období 2021–2026. Mise Horizontu Evropa jsou reakcí na potřeby a výzvy definované v Cílech udržitelného rozvoje OSN, Zelené dohodě pro Evropu a Evropském plánu boje proti rakovině. Pro programové období je stanoveno 5 misí:

Zaměření misí a první plánované výzvy pro období 2021-2022 jsou blíže popsány v pracovním programu pro mise programu Horizont Evropa.

Cílem misí je konkrétně, měřitelně, a přitom dostatečně ambiciózně přispět k řešení zásadních výzev současného světa. Mise integrují cíle a dopady dílčích projektů do tematicky zaměřeného portfolia, které odpovídá širšímu cíli, jehož popis však umožňuje stanovit konkrétní měřitelné ukazatele, které zásadně přispějí k řešení problematiky celosvětového významu. Každá mise má pro splnění svých cílů svůj vlastní harmonogram a rozpočet.

Mise Rakovina podpoří aktivity zaměřené na rozšíření prevence a zlepšení léčby rakoviny, záchranu více životů a zajištění lepší kvality života pacientům, kteří tímto onemocněním trpí nebo je prodělali. Mise bude probíhat v časovém rámci deseti let s cílem zachránit do roku 2030 více než tři miliony životů prostřednictvím rozsáhlejší prevence a zajistit, aby více lidí žilo déle a lépe. Mise Rakovina je součástí naplnění Evropského plánu boje proti rakovině a představuje hlavní směry a cíle v oblasti výzkumu a inovací jako příspěvků k jeho naplnění. Plán v oblasti implementace mise popisuje výhledová studie.

Vyhlášené výzvy

Improving and upscaling primary prevention of cancer through implementation research

Code: HORIZON-MISS-2022-CANCER-01-01
Action type: RIA
Opening: 24. 05. 2022
Deadline: 07. 09. 2022
Budget (EUR million): 50
Expected EU contribution per project (EUR million): 3 – 8
Number of projects expected to be funded: 10

Expected Outcome:

  • Citizens will benefit from the outcomes of evidence-based, tailored and affordable primary prevention programmes targeting known cancer risk factors and health determinants, including behavioural factors, that are tailored to the specific needs of local communities and effectively adopted;
  • Healthcare professionals and patient organisations will be able to provide evidence-based information targeted at individuals and families on cancer prevention, including through vaccination, improved health literacy, issuing of better guidelines and counselling;
  • Regional and national policymakers and authorities will engage in implementing and scaling-up the most suitable prevention programmes, including possible legislative policies;
  • Civil society, charities, foundations, and innovators will seize opportunities to further upscale and innovate primary prevention programmes at local, urban, rural, regional, national or international level.

Scope:

  • Implement and upscale of evidence-based primary cancer prevention interventions, at local, regional or national level, addressing known risk or protective factors and determinants.
  • Identify and address the bottlenecks and barriers that might influence uptake and implementation of cancer prevention programmes in accessible, affordable and equitable ways, and their impact in a defined public health context.
  • Provide evidence and recommendations to inform policy and decision-makers and propose a pathway to integrate the intervention into local, regional or national health systems, policies and practices.

Clinical trials and translational research are not within the scope of this topic.This topic requires the effective contribution of SSH disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

This topic requires the effective contribution of SSH disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

Pragmatic clinical trials to optimise treatments for patients with refractory cancers

Code: HORIZON-MISS-2022-CANCER-01-03
Action type: RIA
Opening: 24. 5. 2022
Deadline: 7. 9. 2022
Budget (EUR million): 60
Expected EU contribution per project (EUR million): 4 - 6 
Number of projects expected to be funded: 10

Expected Outcome:

  • Optimised and affordable treatment interventions that increase their quality of life, across EU regions, Member States and Associated Countries;
  • Healthcare professionals and academia will generate clinical evidence, by evaluating effectiveness in randomised or cluster-randomised academic investigator-initiated pragmatic clinical trials, how to best perform and deploy evidence-based treatment interventions that improve outcomes in real life for routine healthcare, including quality of life, for cancer patients who often present with co-morbidities;
  • National healthcare providers, policymakers and authorities in EU Regions, Member States and Associated Countries will have the evidence to implement optimised and affordable treatments in their healthcare systems, including in everyday medical practice.

Scope:

  • Design and conduct randomised or cluster-randomised academic investigator-initiated pragmatic clinical trials to deliver effective and evidence-based treatment interventions for implementation by healthcare systems at the level of local communities, EU Regions, Member States and Associated Countries, taking into account socio-economic and biological stratification, such as biology of the disease, gender, cancer stage, and age.
  • Address treatment interventions for patients with refractory cancers (cancers with a 5-year overall survival of less than 50% from time of diagnosis) at any stage of the disease, for any cancer subtype, in any age group or part of society.
  • The primary and secondary endpoints of the pragmatic clinical trial should target overall survival, patient-preferred clinical benefit, patient-reported outcomes and quality of life issues considered important by and for cancer patients and their caregivers. Such endpoints should be defined together with patients and their caregivers through research models that use open knowledge, (social) innovation systems and support end-user engagement (e.g. living labs).
  • Implementers of pragmatic clinical trials and trial results should include physicians, academia, patients and their caregivers, patient representatives, payers, charities and foundations, research organisations, civil society, regional and national research and innovation organisations, and health authorities.
  • Successful pragmatic clinical trials, including their analyses, should be completed within 5 years after the start of the project. Translational research is not within the scope of this topic.

This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info